New Hope for Early-Stage Alzheimer's Disease: Can We Modify the Disease Pathway by Targeting Amyloid-β?**

Sponsored By: Answers in CME (This activity is supported by an educational grant from Biogen)

Date/Time: Tuesday, October 19, 2021 - 8:30 AM – 9:30 AM
Log in to Add to My Schedule


The objective of this activity series is to improve neurologists’ knowledge and competence in evaluating the rationale behind selectively targeting neurotoxic soluble amyloid-β oligomers in early-stage AD, assessing the latest evidence on the efficacy and safety of emerging late-stage anti-amyloid-β immunotherapies and proposing a patient-centered approach that will maximize the benefits of these emerging therapies.



  • Marwan N. Sabbagh, MD; Cleveland Clinic

  • James E. Galvin, MD, MPH; University of Miami Miller School of Medicine

  • Lueva Demps; Alzheimer's Caregiver